Prøve GULL - Gratis

Bio Spectrum - BioSpectrum India Dec 2024

filled-star
Bio Spectrum

Gå ubegrenset med Magzter GOLD

Lese Bio Spectrum sammen med 9000+ andre magasiner og aviser med bare ett abonnement  

Se katalog

1 måned

$14.99

1 år

$149.99

$12/month

(OR)

Abonner kun på Bio Spectrum

Kjøp denne utgaven: BioSpectrum India Dec 2024

1 problemer som starter fra BioSpectrum India Dec 2024

12 problemer som starter fra BioSpectrum India Dec 2024

Kjøp denne utgaven

$0.99

1 år

$10.99

Please choose your subscription plan

Avbryt når som helst.

(Ingen forpliktelser) ⓘ

Hvis du ikke er fornøyd med abonnementet, kan du sende oss en e-post på help@magzter.com innen 7 dager etter abonnementets startdato for full refusjon. Ingen spørsmål - lover! (Merk: Gjelder ikke for enkeltutgavekjøp)

Digitalt abonnement

Øyeblikkelig tilgang ⓘ

Abonner nå for å begynne å lese umiddelbart på Magzter-nettstedet, iOS, Android og Amazon-appene.

Verifisert sikker

betaling ⓘ

Magzter er en verifisert Authorize.Net-forhandler. Les mer

I dette nummeret

BioPharma’s Transformative & Strategic OUTLOOK 2025 The Indian biopharma industry witnessed notable transformative developments and announcements, marked by innovation, regulatory advancements, and market expansion this year. From achieving global recognition in biosimilars to advancing biomanufacturing capabilities and precision therapeutics, the sector has solidified its role as a key player in the global pharmaceutical landscape. This progress underscores India’s strategic focus on leveraging its robust infrastructure, skilled talent pool, and government support to meet the evolving demands of the healthcare industry. Key developments in 2024 include an increase in biosimilar approvals, enhanced collaborations for biologics and vaccines, and a focus on potential investments in cutting-edge technologies like Artificial Intelligence (AI), continuous manufacturing, and automation through biofoundries. Looking ahead, the industry is well-positioned to align with emerging trends that are shaping the global biopharma landscape for 2025 and beyond.These include the growing emphasis on precision medicine, a shift towards sustainablebiomanufacturing practices, and an increase in demand for advanced therapies such as cell and gene therapies. With over $200 billion worth of biologic patents set to expire by 2030, Indiancompanies are poised to play a pivotal role in driving the next wave of innovation and accessibilityin biologics and biosimilars.

Bio Spectrum Description:

India's leading publication that covers the business of bio-technology. With comprehensive analyses of policy issues, products and services across the bio-pharma, bio-informatics, bio-infrastructure and bio-agriculture segments, it is the industry's most authoritative source of information.

Nylige utgaver

Spesielle problemer

  • March 2013

    March 2013

Relaterte titler

Populære kategorier